French drug maker Genfit said Monday that its lead drug, elafibranor, failed to improve outcomes for patients with the fatty liver disease NASH, according to an interim analysis of a late-stage clinical trial.
“These results are highly disappointing,” Genfit CEO Pascal Prigent said in a statement. The company plans to review additional data and consult with regulators before determining if development of elafibranor should continue.
About the Author Reprints
